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Abstract 15 
Modern gene therapies aim to prevent the inheritance of mutant mitochondrial DNA 16 
(mtDNA) from mother to offspring by using a third-party mtDNA background. 17 
Technological limitations mean that these therapies may result in a small amount 18 
of maternal mtDNA admixed with a majority of third-party mtDNA. This situation is 19 
unstable if the mother's mtDNA experiences a proliferative advantage over the 20 
third-party mtDNA, in which case the efficacy of the therapy may be undermined. 21 
 2 
Animal models suggest that the likelihood of such a proliferative advantage 22 
increases with increasing genetic distance between mother and third-party mtDNA, 23 
but in real therapeutic contexts the genetic distance, and so the importance of this 24 
effect, remains unclear. Here we harness a large volume of available human 25 
mtDNA data to model random sampling of mother and third-party mtDNAs from 26 
real human populations. We show that even within the same haplogroup, genetic 27 
differences around 20-80 SNPs are common between mtDNAs. These values are 28 
sufficient to lead to substantial segregation in murine models, over an organismal 29 
lifetime, even given low starting heteroplasmy, inducing increases from 5% to 35% 30 
over one year. Randomly pairing mothers and third-party women in clinical 31 
contexts thus runs the risk that substantial mtDNA segregation will compromise the 32 
beneficial effects of the therapy. We suggest that choices of ‘mtDNA donors’ be 33 
based on recent shared maternal ancestry, or, preferentially, explicit haplotype 34 
matching, in order to reduce the potential for problems in the implementation of 35 
these therapies. 36 
 37 
Introduction  38 
Mitochondria are small organelles within eukaryotic cells that are vital for the 39 
normal aerobic production of ATP, the ‘universal’ biochemical energy carrier. Each 40 
mitochondrion, of which there are many in any given cell, carries at least one copy 41 
of its own, small genome (mitochondrial or mtDNA), distinct from the large genome 42 
stored in the nucleus. While there are good reasons for retaining some genes in 43 
 3 
the mitochondrion (Johnston and Williams, 2016), a challenging biochemical 44 
environment and comparative lack of efficient DNA repair mechanisms allows a 45 
higher mutation rate there than in the nucleus (Alexeyev et al. , 2013).  46 
 47 
Differences in the sequence of mitochondrial DNA can arise at the level of 48 
individuals (population diversity) or different mitochondria in the same cell 49 
(heteroplasmy – see below). In humans, mtDNA is inherited uniparentally, via the 50 
mother's egg cell; recombination is usually negligible between human mtDNAs 51 
(Hagelberg, 2003, Hagstrom et al. , 2014). Given the non-recombining nature of 52 
the mitochondrial genome, such polymorphisms as exist can be expressed in 53 
terms of a straightforward phylogenetic tree (see Fig. 1A). The sum of 54 
polymorphisms in an mtDNA sequence is known as a haplotype, and any 55 
hierarchical clade of haplotypes is a haplogroup. Since inheritance is uniparental, 56 
mtDNA haplogroups are strongly susceptible to genetic drift, and this has given 57 
rise to pronounced haplogroup pattern differences between geographical areas, 58 
especially on a continental scale (see Fig. 1B). 59 
 60 
Mitochondrial diversity in humans is often neutral or near-neutral (Chinnery and 61 
Hudson, 2013), although an increasing volume of research in animal models and 62 
humans suggests that non-pathogenic mtDNA variants can be associated with 63 
some phenotypic effects, from livestock fertility to longevity and disease 64 
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susceptibility (Dowling, 2014, Latorre-Pellicer et al. , 2016, St John, 2016, Tsai and 65 
St John, 2016, Wallace, 2015, Wallace and Chalkia, 2013). We note that, while 66 
evidence exists for a range of phenotypic effects, flawed analyses have in some 67 
cases led to several statistically unsupported claims of mtDNA links to disease 68 
(Johnston, 2015).  69 
 70 
While the phenotypic effects of some mtDNA variants are relatively mild, certain 71 
mtDNA mutations in humans have dramatic phenotypic consequences, causing 72 
fatal, incurable diseases (for example, mt3243A>G, causing the inherited disease 73 
MELAS), which often manifest when the proportion of mutated mtDNA molecules 74 
in a cellular population exceeds a threshold (Taylor and Turnbull, 2005, Wallace 75 
and Chalkia, 2013). Clinical approaches to prevent the inheritance of diseases 76 
resulting from damaging mutations in mtDNA are a focus of current medical 77 
research. Cutting-edge therapies including pronuclear transfer and chromosomal 78 
spindle transfer attempt to address the inheritance of mutant mtDNA from a 79 
maternal carrier by transferring the nuclear genome (either as the pair of pronuclei 80 
or the chromosomal spindle) into a third-party, enucleated oocyte or zygote with 81 
non-pathogenic mtDNA (Brown et al. , 2006, Burgstaller et al. , 2015, Craven et al. 82 
, 2010, Tachibana et al. , 2009) (Fig. 2). These therapies thus aim to place parental 83 
nuclear DNA on a healthy mitochondrial background with no mtDNA from the 84 
mother present. However, technological limitations currently mean that carryover is 85 
possible, whereby some of the mother's mtDNA may be carried into the third-party 86 
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cell with the transferred nuclear genetic material. These therapies can thus lead to 87 
the coexistence of several distinct sequences within cellular mtDNA populations. 88 
First, the non-pathogenic mtDNA from the third-party oocyte donor is present. 89 
Second, due to carryover, non-pathogenic mtDNA from the mother may be 90 
present. Third, due to carryover, pathogenic (mutant) mtDNA from the mother may 91 
be present (Fig. 2). The resulting complex system may give rise to phenotypic 92 
effects due to differences between admixed mtDNA types (Burgstaller et al., 2015) 93 
and references therein, and between the nucleus and different mtDNA types 94 
(reviewed in (Reinhardt et al. , 2013)), highlighted by very recent work in mouse 95 
model (Latorre-Pellicer et al., 2016). Previous work has reviewed the potential 96 
implications of these effects on gene therapies (Morrow et al. , 2015, Reinhardt et 97 
al., 2013). In this article we will focus on the possibility, and implications, of 98 
proliferative differences between different mtDNA types.  99 
The above admixture of mtDNA types is stable if mother and oocyte donor mtDNA 100 
experience no proliferative differences (Fig. 2, centre), and if the oocyte donor 101 
haplotype experiences a proliferative advantage then carried-over mtDNA will 102 
generally be reduced over time (Fig. 2 left). However, a general proliferative 103 
advantage of the mother's haplotype can in principle lead to the amplification of the 104 
associated pathological mutation, working against the desired effect of the therapy 105 
to remove this mutation (Fig. 2 right). This amplification can in principle occur even 106 
if the pathological mutation itself experiences a selective disadvantage – if this 107 
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disadvantage is of lower magnitude than the proliferative difference between 108 
haplotypes, the latter effect will still dominate. 109 
In a wide selection of mammalian species, such proliferative differences between 110 
mtDNA haplotypes have been shown to exist (St John et al. , 2010). Pronounced 111 
differences have been shown in various mouse models e.g. (Burgstaller et al. , 112 
2014, Sharpley et al. , 2012), pigs (Takeda et al. , 2006), mini-pigs (Cagnone et al. 113 
, 2016), and cattle (Ferreira et al. , 2010). Sets of models and studies exhibiting 114 
this behaviour are reviewed in (Burgstaller et al., 2015, St John, 2012). Recent 115 
work in human cell lines (Yamada et al. , 2016) has illustrated that pronounced 116 
changes in the balance of mtDNA haplotypes in cellular populations can occur over 117 
time, with an initially small population of one haplotype (H1) becoming dramatically 118 
amplified and subsequently reduced through cell passages when admixed with a 119 
distantly-related human haplotype (L3). Recent results from a human stem cell line 120 
ultimately derived from an instance of pronuclear transfer explicitly demonstrate 121 
that amplification of carried-over mtDNA can occur after therapy implementations, 122 
in some instances from 4% to >40% of the cellular population over 10 passages, 123 
even with genetically similar (same haplogroup) mtDNA sequences (Hyslop et al. , 124 
2016). 125 
While the direction and tissue-dependence of differential proliferation are currently 126 
difficult to predict for a given system, the expected magnitude of the difference 127 
depends on the genetic distance between haplotypes (Burgstaller et al., 2014) (Fig. 128 
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3). An important question to consider in gene therapies is thus, given the mtDNA 129 
diversity in human populations, what genetic distances are likely to arise in nuclear 130 
mother-oocyte donor pairings in therapeutic contexts, and what is the magnitude of 131 
the proliferative differences (Fig. 2) these distances will produce? 132 
 133 
 134 
If ∏𝑖𝑖𝑖𝑖 is the number of non-identical bases between two mtDNA genomes, i and j, 135 
then, intuitively, identical mtDNAs (∏𝑖𝑖𝑖𝑖 = 0) would be expected to behave 136 
identically, but the more different the mtDNAs (∏𝑖𝑖𝑖𝑖 > 0), the larger is the 137 
proliferative difference generally expected between the two. We define 138 
heteroplasmy, h, as the proportion of one ‘foreign’ mtDNA haplotype in a cellular 139 
admixture: hence, if a cell contains H0 mtDNAs of its ‘native’ haplotype and H1 140 
mtDNAs of a ‘foreign’ haplotype, ℎ = 𝐻𝐻1/(𝐻𝐻0 +  𝐻𝐻1). 141 
Proliferative differences between haplotypes can be measured as a quantity 𝛽𝛽, a 142 
rate of proliferation of one mtDNA over another, overcoming the limitations inherent 143 
in considering absolute differences in heteroplasmy percentages (see SI for a 144 
formal definition). For example, proliferative differences of average magnitude 145 |𝛽𝛽| ≃ 0.008 per day have been measured between two mtDNA types of ∏𝑖𝑖𝑖𝑖 ≃ 100 146 
in the livers of mice; this value of 𝛽𝛽 corresponds to an amplification of h from 0.05 147 
(5% of one haplotype) to 0.49 (49% of that same haplotype) over one year 148 
(Burgstaller et al., 2014). This pronounced rate of change is supported by results in 149 
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a range of other mammalian models (including rapid fixation of an initial limited 150 
mtDNA haplotype in cattle (Koehler et al. , 1991) and the aforementioned results 151 
from human cell lines where changes from <10% to >40% occur over a small 152 
number of cell passages (Hyslop et al., 2016). 153 
A subset of recent evidence for proliferative differences between mtDNA 154 
haplotypes in mice is shown in Fig. 3. Fig. 3A shows inferred values of |𝛽𝛽|, and the 155 
magnitude of proliferative differences between mtDNAs, in a variety of tissues for 156 
three mtDNA pairs (where ∏𝑖𝑖𝑖𝑖 = 18, 86, and 107). Fig. 3B shows the predictions 157 
that this behaviour of 𝛽𝛽 makes about absolute changes in heteroplasmy, for two 158 
putative admixtures beginning with 5% and 20% of a ‘foreign’ haplotype. For 159 
example, a haplotype differing from the ‘native’ type by ∏𝑖𝑖𝑖𝑖 ≃ 100 may readily 160 
experience amplification from 5% to 50% over one year. 161 
For simplicity, these plots are limited to the behaviour over one year, but the trends 162 
are observed to continue throughout organismal lifetimes. For example, one 163 
observation in (Burgstaller et al., 2014) showed heteroplasmy in liver tissue rising 164 
from 5.9% to 81.8% over 680 days for a particular mtDNA pairing where ∏𝑖𝑖𝑖𝑖 =165  108. There is thus evidence that, in mice, nucleotide differences around ∏𝑖𝑖𝑖𝑖 ∼ 100 166 
are associated with proliferative differences capable of amplifying an admixed 167 
haplotype from a 5% minority to a pronounced cellular majority over the course of 168 
an organismal lifetime. But what are standard values of ∏𝑖𝑖𝑖𝑖 in actual human 169 
populations? And is this magnitude of genetic diversity expected to give rise to 170 
clinically relevant mtDNA behaviour, given that a mutant mtDNA load of 40-60% is 171 
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often sufficient to cause morbidity, and it still poorly known what ‘safe’ levels may 172 
be in most cases (Wallace and Chalkia, 2013)? 173 
Existing studies have characterised the nucleotide differences in contemporary 174 
human populations, finding typical differences of dozens of nucleotides across 175 
modern Europeans (Fu et al. , 2012), greater diversity in Africa than in Europe 176 
(Briggs et al. , 2009), and results confirming and expanding these observations 177 
across a broader geographical range (Lippold et al. , 2014). A modern workflow 178 
has been developed to address related evolutionary questions (Blanco et al. , 179 
2011). However, to our knowledge, the interpretation of these statistics in terms of 180 
mtDNA segregation possibility and implications for disease is currently absent, as 181 
is an attempt to characterise the expected diversity in modern populations 182 
combining social (census) and biological (sequence) data. 183 
 184 
Materials and Methods 185 
Materials – None. 186 
Methods – We took a data-driven approach, harnessing the large numbers of 187 
human mtDNA sequence data now available through the NCBI database, as well 188 
as haplogroup data in the literature. mtDNA molecules may be categorised, via the 189 
presence or absence of diagnostic SNPs, into haplogroups, which are typically 190 
designated by an alphanumeric code and follow a moderately complex hierarchy. 191 
For example, at the coarsest level, all human mtDNAs so far recorded fall into 192 
haplogroup L. Subsets of L include N (which in turn includes R, containing H and 193 
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V, etc.) and W, X, Y and others. A simplified tree of haplogroups is shown in Fig. 194 
1A and illustrative geographical distributions are shown in Fig. 1B. 195 
Data on the haplogroup makeup of ‘pre-colonial populations’, i.e. before early 196 
modern population mixing, from different geographical regions is available via 197 
MitoMAP (Lott et al. , 2013). These data can be used to estimate the probability 198 
that an individual with maternal ancestry from a given region belongs to a given 199 
haplogroup. 200 
Many specific mtDNA sequences corresponding to individual humans belonging to 201 
a given haplogroup are available via NCBI. Using these data, we sought to identify 202 
the expected genetic differences between pairs of individual, real human mtDNAs. 203 
To estimate these expected differences, we first characterised the expected 204 
differences between specific mtDNA samples within and between different 205 
haplogroups.  206 
We obtained the > 30𝑘𝑘 mtDNA sequences available from NCBI Nucleotide 207 
database (NCBI, 2015). Of these sequences ∼ 7.6𝑘𝑘 had straightforwardly 208 
interpretable haplogroup information, where the initial letter of the /haplogroup field 209 
was taken to be the haplogroup label. We categorised these records by this initial 210 
letter, then employed the following sampling protocol. Given a pair of haplogroups 211 {ℋ1,ℋ2}, we picked at random a sequence belonging to ℋ1 and picked at random 212 
a sequence belonging to ℋ2 (ensuring that the two sequences were not the same 213 
sample if ℋ1 = ℋ2,). We used BLAST to record the number of sequence 214 
differences between these specific sampled sequences. For the purposes of this 215 
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report we recorded the number of non-identical bases as the nucleotide difference 216 
∏𝑖𝑖𝑖𝑖; we also note that indels commonly exist between sampled mtDNA sequences, 217 
further contributing to mtDNA diversity. We then built up a distribution of sequence 218 
differences over many (n=1000) sampled pairs of specific human mtDNAs from the 219 
given pair of haplogroups. 220 
To connect more explicitly with medical policy, we next changed the scale of our 221 
analysis from haplogroups per se to the estimated haplogroup profiles of real 222 
human populations. First, we employed heuristic data from the MitoMAP project 223 
(Lott et al., 2013) estimating the haplogroup makeup of pre-colonial populations 224 
from different regions of the world, while noting that the actual census populations 225 
will usually have a very different makeup, especially in New World countries that 226 
experienced extensive overseas colonization. For each region, we randomly chose 227 
two haplogroups, each with a probability corresponding to that haplogroup's 228 
representation in the region of interest. We then randomly chose two specific 229 
mtDNA sequences from those two haplogroups. As above, we then used BLAST to 230 
determine the genetic difference between those specific sequences. We repeated 231 
this process many times to build up an expected distribution of the genetic 232 
differences between two randomly chosen members of the human population from 233 
that region. 234 
As the UK is on the cusp of implementing gene therapies based on nuclear 235 
transfer, we then performed a more rigorous, population-based analysis for Britain. 236 
In order to estimate the probable levels of nucleotide diversity (∏𝑖𝑖𝑖𝑖) in mtDNA 237 
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between two randomly selected British women, and hence the likely magnitude of 238 
proliferative differences between their mtDNA, a haplogroup profile of Britain was 239 
assembled, based on over 4,600 individuals. The majority of the UK samples 240 
represent ethnic Britons. To account for the fact that the modern UK population 241 
consists of many ethnicities, approximations of mtDNA haplogroup distributions for 242 
the two largest cities in the UK (London and Birmingham) were also constructed. 243 
These distributions are estimates, based on data from the 2011 census, 244 
immigration data, and published mtDNA haplogroup data for areas from which 245 
there has been mass immigration into the UK (see SI for details). 246 
For each ethnic census category, an estimate of probable haplogroup composition 247 
was created (see SI for details on calculations), and the frequency values scaled 248 
by the numerical census data to yield expected haplogroup frequencies in London 249 
and Birmingham.  For simplicity, the single letter level of nomenclature is used, 250 
with the exception of superhaplogroup L, for which its subgroups L0-3 are included. 251 
 252 
Results 253 
 Fig. 4A shows the resulting statistics on differences between sampled mtDNA 254 
sequences between haplogroup pairs. Several intuitive features are immediately 255 
observable. First, haplogroup L displays noticeably more intra-haplogroup 256 
differences than any other haplogroup. L haplogroups constitute the majority of 257 
African haplogroups (and have very deep branching times relative to non-African 258 
haplogroups) and are thus expected to include the most genetic diversity (Behar et 259 
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al. , 2008). Second, with the exception of L, diagonal elements (i.e. samples from a 260 
haplogroup compared to samples from the same haplogroup) show less diversity 261 
than off-diagonal elements (i.e. samples from one haplogroup compared to 262 
samples from a different haplogroup). Third, haplogroup pairings which are 263 
expected to be similar (for example, sister clades H and V) show decreased 264 
genetic diversity. The inset shows a breakdown of the L haplogroup into its 265 
immediate subgroups. 266 
A notable result from this analysis is that between haplogroups, differences of ∼50 267 
SNPs are common, and, even within haplogroups, differences of ∼20 SNPs are 268 
not uncommon. This level of diversity may not seem substantial when compared to 269 
the ∼16 kilobases of total human mtDNA, but we draw attention to our previous 270 
observations that differences of ∼20 SNPs were enough to induce significant 271 
proliferative differences between haplotypes in mice, who also have a ∼16kb 272 
mtDNA genome (Burgstaller et al., 2014). As shown in parentheses in Fig. 4A, the 273 
magnitudes of ∏ that likely emerge from pairwise haplotype samples match those 274 
responsible for dramatic mtDNA heteroplasmy changes in mouse models. 275 
Fig. 4A also provides a means of identifying a ‘partner’ for a given haplogroup that 276 
minimizes ∏ and hence the likelihood of damaging segregation. For example, 277 
given a mother with haplogroup B and a choice between donors from C, V, and L, 278 
Fig.4A shows that the B-V pairing minimizes maximum ∏, and thus affords the 279 
lowest risk of high segregation (see Discussion).  280 
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Table 1 gives the estimated haplogroup makeup of the UK and two major cities, 281 
based on a combination of census and immigration data and a survey of worldwide 282 
mtDNA sequences (see Methods and SI). We underline that these quantities are 283 
principled estimates, but the summary statistics that arise from these estimates are 284 
robust to variation in the exact population frequencies, and is consistent with the 285 
behaviour expected from an ethnically mixed population based on more direct 286 
estimates (see below).  287 
Fig. 4B illustrates the distribution of nucleotide differences between individuals 288 
sampled from geographical regions, and rural vs. urban UK based on estimates in 289 
Table 1, in this manner. It is immediately noticeable that pairs of individuals from 290 
Africa generally exhibit more diversity than pairs chosen from other regions, but it 291 
is striking that the expected genetic difference in many geographic regions is 292 
around ∏𝑖𝑖𝑖𝑖 ∼ 40-50 SNPs, often with a range between 10-100 SNPs. The 293 
substantial diversity expected in the UK and its cities is of a consistent magnitude 294 
with that expected from its population history, involving admixtures of African and 295 
Asian immigrants in addition to its original European state. Again, parenthesized 296 
numbers in Fig. 4B illustrate that these magnitudes of ∏ are readily able to induce 297 
pronounced heteroplasmy shifts in mice. Taken together, these results 298 
demonstrate that expected levels of mtDNA diversity in modern human populations 299 
are of comparable magnitude to those responsible for substantial segregation bias 300 
in existing mammalian models, and so therapies that randomly pair women from 301 
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these populations may engender potentially detrimental heteroplasmy changes 302 
over time. 303 
 304 
Discussion 305 
Our analysis clearly shows that, even within a geographical region restricted to the 306 
point of being dominated by a single mtDNA haplogroup, a ∏𝑖𝑖𝑖𝑖 = 10 − 100 is 307 
expected between randomly sampled individuals from that region. On a continental 308 
scale, expected differences are highest in Africa, as predicted from our knowledge 309 
of human population history, and comparably lower elsewhere. Comparably high, 310 
however, are the differences in the largest urban populations of the UK, where 311 
oocyte donor therapies will be implemented. 312 
In mice, proliferative differences between haplogroups with ∏𝑖𝑖𝑖𝑖 ∼ 100 were 313 
sufficient in some tissues to cause amplification of one mtDNA type from 0.05 to 314 
0.64 (i.e. a small representation to a notable majority) over an organismal lifetime 315 
(Fig. 2B). There remains a wide range of questions involving the mapping from the 316 
murine model to the human system. One criticism of our argument may be that 317 
mtDNA segregation in humans may progress more slowly than in mice, reducing 318 
the magnitude of the effects we consider. However, segregation in humans has 319 
been observed to occur more rapidly than in mice (Wallace and Chalkia, 2013). 320 
Furthermore, evidence exists for pronounced segregation of a pathological 321 
mutation over very short times during embryo-fetal development (Monnot et al. , 322 
2011), suggesting the presence of mechanisms in humans that support fast 323 
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segregation, and which could in principle also act on non-pathological mutations. 324 
Recent results in human cell lines (Hyslop et al., 2016, Yamada et al., 2016) 325 
showing fast changes in mtDNA population structure over passages support the 326 
possibility of fast segregation. These rapid mtDNA dynamics are supported by 327 
evidence from other large mammalian models, including the rapid fixation of 328 
mtDNA haplotypes in cattle (Burgstaller et al., 2015, Koehler et al., 1991) Even in a 329 
conservative case where mtDNA turnover rates are scaled by organismal lifetimes, 330 
amplification over the (longer) human lifetime will still be anticipated by analogy 331 
with the murine system. An important clinical example of the potentially high 332 
mtDNA segregation in human disease (again involving a pathological mutation) is 333 
described in Ref.(Mitalipov et al. , 2014), in which an embryo selected for its low 334 
(12%) load of the 3243 mutation (Treff et al. , 2012) developed into an infant with 335 
>40% loads in blood and urine at six weeks of age, presenting with a range of 336 
(possibly unrelated) metabolic pathologies.  337 
It is worth noting that, in addition to the unpredictability of segregation direction, the 338 
rate at which mtDNA segregation occurs is not simple and constant – rather, it can 339 
depend on tissue type, organismal age and developmental stage (Burgstaller et al., 340 
2014), and complicating processes including the mtDNA bottleneck (Johnston et al. 341 
, 2015). In addition, increasing evidence that mtDNA variants may influence fertility 342 
and development (St John, 2012, St John et al., 2010) suggests further potential 343 
complications as mtDNA populations both influence and are influenced by 344 
developmental dynamics. Given these complications, it is not unreasonable to think 345 
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that the ‘averaged’ rates reported here may be underestimates for a particular time 346 
period. We therefore highlight that, even from a conservative calculation of 347 
segregation rates, the likely genetic differences between humans randomly 348 
sampled from a population may well allow substantial amplification of a 349 
disease-carrying mtDNA haplotype over the timescale of a human lifetime. 350 
 351 
We must also consider whether randomly sampling NCBI sequences is a good 352 
model for the mtDNA pairings likely to be involved in gene therapies. The counter-353 
example of this would be a population consisting of many individuals with identical 354 
mtDNA sequences and a small number of individuals with different sequences. The 355 
NCBI, which assigns records to unique sequences, will likely have one record for 356 
the common sequence and one each for the rare different sequences. In this case, 357 
uniformly sampling NCBI would underestimate the population fraction with the 358 
common sequence, and thus tend to overestimate mtDNA diversity. However, the 359 
ubiquity of many-SNP differences between records (see Fig.4) suggests that this 360 
problematic population structure is unlikely, and indeed, several contemporary 361 
studies have observed differences between each individual sample (Fu et al., 362 
2012, Lippold et al., 2014). Additionally, socio-economic factors will give rise to 363 
structure in the pairings in clinical applications (which may either decrease or 364 
increase the expected ∏𝑖𝑖𝑖𝑖). Despite these complications, we consider our 365 
approximations appropriate for considering first-order bounds of likely behaviour in 366 
these populations exhibiting realistic human diversity. 367 
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The danger of pathological mutations ‘hitchhiking’ on favoured haplotype 368 
backgrounds and being amplified along with the haplotype is described in the 369 
introduction and has been discussed previously (Burgstaller et al., 2014, 370 
Burgstaller et al., 2015). An additional danger is the amplification of an initially rare 371 
mtDNA haplotype to the point where it competes with the dominant mtDNA type in 372 
a cell and causes pathologies through mismatched mitochondrially encoded 373 
protein subunits or other mechanisms (Burgstaller et al., 2015). The co-occurrence 374 
in a cell of two different, but both separately non-pathogenic, mtDNAs has been 375 
observed to result in adverse physiological changes (Sharpley et al., 2012), and 376 
so-called mito-nuclear incompatibilities between nuclear and 'foreign' mtDNA 377 
content can induce phenotypic effects (Latorre-Pellicer et al., 2016) –  resulting in 378 
potential implications for gene therapies that have been reviewed elsewhere 379 
(Morrow et al., 2015, Reinhardt et al., 2013). Segregation between mtDNA 380 
haplotypes, allowing an initially rare haplotype to proliferate and become amplified 381 
within a cell, has the potential to manifest and exacerbate all of these potential 382 
issues. 383 
To diminish the likelihood of potentially harmful mtDNA segregation, which we 384 
argue is likely given the mtDNA diversity in the modern UK population, we urge 385 
experts involved in the implementation of these therapies to consider ‘haplotype 386 
matching’, i.e. choosing an oocyte donor with mtDNA as similar as possible to the 387 
mother's in clinical approaches. Methods to match haplotypes (minimise ∏𝑖𝑖𝑖𝑖) could 388 
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include choosing maternal relatives of the mother with low or zero proportions of 389 
the pathological mutation under consideration, or choosing donors from a 390 
haplogroup as similar as possible to the mother’s. To illustrate this latter strategy, 391 
Fig. 5 shows the range of expected ∏ values that could arise when a third-party 392 
donor is paired with a mother from haplogroup H1a. If no haplotype matching is 393 
employed, and the third-party donor is randomly sampled from our estimated 394 
London population, a maximum ∏ around 100 is possible (due to the pronounced 395 
population diversity illustrated in Fig. 4B). Choosing a donor from haplogroup H 396 
decreases this maximum value to around 36 (that is, the maximal within-H 397 
diversity, shown on the diagonal of Fig. 4A). More detailed matching, specifically 398 
choosing another H1a woman as the third-party, further limits the maximum ∏ to 399 
approximately 17. These lower values achieved through haplotype matching 400 
dramatically decrease the expected potential heteroplasmy changes (for example, 401 
in mice (Fig 2), from a maximum of 5% → 49% over one year for ∏ = 100 to 5% → 402 
8% over one year for ∏ = 17), thus immediately limiting the potential for 403 
detrimental segregation.  Our results, and future findings from more detailed 404 
studies, can help provide a strategy for this matching process – given a mother of 405 
known mtDNA haplogroup, choose from available oocyte donors so as to minimise 406 
the maximum genetic distance given in Fig. 4. Such haplotype matching, which is 407 
in principle technically straightforward and economically marginal, decreases the 408 
risk of inadvertently choosing an mtDNA pairing which experiences substantial 409 
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proliferative differences, and thus decreases the risk of manifestation of the 410 
disease the therapy was implemented to prevent. 411 
 412 
Table 1. Estimated haplogroup frequencies in the British population UK – 413 
majority ethnic Britons, exclusive of large urban areas, London, Birmingham –414 
census and immigration data based estimates (see SI). 415 
HG UK % London % Birmingham 
% 
A 0.0% 0.6% 0.5% 
B 0.0% 1.1% 0.7% 
C 0.0% 0.3% 0.2% 
D 0.0% 0.8% 0.5% 
F 0.0% 1.1% 0.8% 
G 0.0% 0.2% 0.2% 
H 45.2% 30.4% 29.9% 
I 4.1% 2.6% 2.6% 
J 12.4% 7.8% 8.2% 
K 8.3% 5.1% 5.3% 
L0 0.0% 1.3% 0.8% 
L1 0.0% 2.4% 1.9% 
L2 0.0% 4.9% 3.8% 
L3 0.1% 4.5% 3.5% 
M 0.0% 10.4% 12.7% 
N 0.0% 0.1% 0.2% 
O 0.0% 0.0% 0.0% 
P 0.0% 0.0% 0.0% 
R 0.1% 2.7% 3.6% 
S 0.0% 0.0% 0.0% 
T 10.5% 6.8% 6.9% 
U 12.6% 11.5% 12.6% 
V 3.2% 1.6% 1.8% 
W 1.5% 1.2% 1.6% 
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X 1.8% 1.2% 1.1% 
other 0.3% 1.3% 0.6%  416  417 
Figure 1. A) Relationship between human mtDNA haplogroups. Haplogroup 418 
labels and tree structure for human mtDNA groups; MRCA is most recent common 419 
ancestor. B) Typical haplogroups in pre-colonial human populations by 420 
approximate geography. We have omitted higher-order haplogroups of which 421 
many sub-groups are presented (e.g. N & R). Based on data from MitoMAP (Lott et 422 
al., 2013) and references therein. 423  424 
Figure 2. mtDNA segregation and gene therapies. A mother may possess two 425 
similar haplotypes, one wild type (blue) and one mutant (blue with red star). 426 
Therapies attempt to use a third-party with a potentially different mtDNA haplotype 427 
(yellow) to provide a healthy mtDNA background. Carryover in these therapies may 428 
result in an admixture of wildtype mother, mutant mother, and wildtype third-party 429 
mtDNA in a cell. If the two haplotypes (blue and yellow) proliferate differently, the 430 
offspring may evolve a predominance of third-party (lower left) or mother (lower 431 
right) mtDNA with time. In the latter case, if mutated mtDNA proliferates at a similar 432 
rate to its ‘carrier’ haplotype, the damaging mutation may be amplified to harmful 433 
levels in cells. 434 
 435 
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Figure 3. mtDNA segregation and genetic differences in mice. A) Magnitudes 436 
of segregation (proliferative differences between mtDNA types) in different tissues 437 
(points) in four different mtDNA pairings from (Burgstaller et al., 2014). More 438 
pronounced segregation is observed in those pairings with the greatest genetic 439 
distance. Red line shows the mean trend of segregation with number of nucleotide 440 
differences; blue line shows the approximate maximum segregation strength 441 
across all tissues for mtDNA pairings with < 100 nucleotide differences. B) Ranges 442 
of expected heteroplasmy in mice after 1 year, given different initial heteroplasmies 443 
(h0) and the mean (lower) and maximal (higher) segregation magnitude observed 444 
in mice. For example, the darker red curve shows that for an mtDNA pairing with 445 
75 nucleotide differences, a maximal increase from ℎ = 0.05 to ℎ ≃ 0.3 is expected. 446 
 447 
Figure 4. A) MtDNA differences between haplogroups. The maximum (outer 448 
halo) and minimum (inner halo) nucleotide differences expected between a pair of 449 
randomly sampled mtDNA sequences (horizontal and vertical axes). The diagonal 450 
corresponds to pairs within the same haplogroup; off-diagonal elements 451 
correspond to pairs of mtDNAs from different haplogroups. Dataset size for each 452 
haplogroup is given in brackets; n=1000 samples were used for each pairing. Max 453 
h change shows, for a given magnitude of genetic diversity, the maximum 454 
expected change in heteroplasmy over one year starting at 5%, based on mouse 455 
models (Fig 3). As described in the text, haplotype labels denote sequences that 456 
fall within a given category and not within any named subcategories of that 457 
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category. Inset shows subgroups of the most-diverse L haplogroup. Red circles 458 
give the magnitudes of genetic differences between the “background” C57BL/6N 459 
mtDNA and the different mtDNA types in the mouse models in Fig. 3. B) MtDNA 460 
differences between geographical regions. In blue, genetic differences between 461 
a pair of individuals randomly sampled from sets modelling populations within a 462 
given region of the world, using the MitoMAP (Lott et al., 2013) estimation of the 463 
(pre-colonial) haplogroup profile of different geographical regions. In black, 464 
expected differences in the general the modern non-urban UK population, and 465 
populations of London and Birmingham. Candlesticks show minimum, mean ± s.d., 466 
and maximum nucleotide differences between simulated pairs sampled from 467 
geographical regions. Explicit sample distributions are given in in lighter colours; 468 
max h change gives maximum expected change in heteroplasmy as in (A). SE 469 
Asia (in grey) has poorly characterised MitoMAP estimates. Red marks, as in (A), 470 
give the magnitudes of genetic differences in the mouse models in Fig. 3. 471 
 472 
Figure 5. MtDNA differences expected with different haplotype matching 473 
strategies for a mother with haplogroup H1a. Distributions of nucleotide 474 
differences (min, mean +- sd, max) expected when pairing mtDNA from haplogroup 475 
H1a with randomly sampled mtDNA from our estimated London population, with 476 
randomly sampled mtDNA from haplogroup H, and with randomly sampled mtDNA 477 
from haplogroup H1a.   478 
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